-
COST-UTILITY ANALYSIS OF SPARSENTAN FOR THE TREATMENT OF IMMUNOGLOBULIN A NEPHROPATHY: A COMPARISON OF SPARSENTAN VERSUS IRBESARTAN AND MODIFIED-RELEASE BUDESONIDE IN SPAIN
Aug 11, 2026, 17:16 PM -
NATIONAL BUDGET IMPACT ANALYSIS OF INTRODUCING COMBINED TRIPLE THERAPY (BUDESONIDE/ GLYCOPYRRONIUM/ FORMOTEROL FUMARATE) TO THE REIMBURSEMENT LIST FOR THE TREATMENT OF MODERATE-TO-SEVERE COPD IN ALGERIA
Aug 11, 2026, 17:16 PM -
LONG-TERM DEMENTIA RISK REDUCTION MAY IMPROVE THE COST-EFFECTIVENESS OF BLOOD PRESSURE LOWERING INTERVENTIONS INCLUDING RENAL DENERVATION
Aug 11, 2026, 17:16 PM -
AN END-TO-END QUALITY ASSURANCE FRAMEWORK FOR REGULATORY-GRADE REAL-WORLD EVIDENCE FROM MULTI-SOURCE ELECTRONIC HEALTH RECORDS
Aug 11, 2026, 17:16 PM -
HEALTH-RELATED QUALITY OF LIFE BY EQ-5D-5L IN MULTIPLE SCLEROSIS: CHARACTERIZATION AND KEY ADVERSE FACTORS' DISUTILITIES
Aug 11, 2026, 17:16 PM -
ADAPTING GLOBAL PATIENT-CENTERED RESEARCH METHODS TO JAPAN: A PRACTICAL FRAMEWORK FOR REGULATORY, ETHICAL, AND SITE-LEVEL IMPLEMENTATION
Aug 11, 2026, 17:16 PM -
SLEEP QUALITY, NONPRESCRIBED SLEEP AID USE, AND MEDICATION SAFETY AWARENESS AMONG UNIVERSITY STUDENTS IN SAUDI ARABIA
Aug 11, 2026, 17:16 PM -
CLINICAL AND ECONOMIC BURDEN OF HEMOLYTIC ANEMIA IN US PATIENTS WITH SICKLE CELL DISEASE: A REAL-WORLD ANALYSIS
Aug 11, 2026, 17:16 PM -
DEVELOPMENT AND VALIDATION OF A PREDICTION MODEL TO ESTIMATE THE HURLEY SCORE IN PATIENTS WITH HIDRADENITIS SUPPURATIVA
Aug 11, 2026, 17:16 PM -
CHARACTERIZING THE HUMANISTIC AND ECONOMIC BURDEN OF HYPOPHOSPHATASIA: A CROSS-SECTIONAL MULTINATIONAL STUDY IN CANADA, COLOMBIA, FRANCE, TURKEY AND THE UK
Aug 11, 2026, 17:16 PM -
SOCIOECONOMIC BURDEN OF DIABETIC MACULAR EDEMA IN ALGERIA: A PREVALENCE-BASED COST-OF-ILLNESS ANALYSIS
Aug 11, 2026, 17:16 PM -
SPATIOTEMPORAL TRENDS AND FORECASTING FOR HUMAN PAPILLOMAVIRUS VACCINATION COVERAGE AND CERVICAL CANCER INCIDENCE AND MORTALITY IN THE EUROPEAN UNION BETWEEN 2010 AND 2030
Aug 11, 2026, 17:16 PM -
BUDGET IMPACT ANALYSIS IN A CHEMOTHERAPY RECONSTITUTION UNIT: SIX-YEAR VALUATION OF PREPARATION CONSUMABLES AND COST RECOVERY PROPOSAL THROUGH A PER-CYCLE BILLING FEE
Aug 11, 2026, 17:16 PM -
BUDGET IMPACT ANALYSIS OF FITUSIRAN FOR THE TREATMENT OF HEMOPHILIA A AND B IN PEDIATRIC AND ADULT PATIENTS IN THE UNITED ARAB EMIRATES (ABU DHABI)
Aug 11, 2026, 17:16 PM -
DISTRIBUTION AND EVIDENCE BASE OF THE EQUITY CRITERION IN ONCOLOGY MULTICRITERIA HEALTH TECHNOLOGY ASSESSMENTS BY RENETSA/INS, PERU (2023-2025)
Aug 11, 2026, 17:16 PM -
HEALTH-RELATED QUALITY OF LIFE AND FUNCTIONAL IMPACTS FOR CAREGIVERS AND CHILDREN LIVING WITH FRRS1L GENETIC DISORDER: A QUALITATIVE STUDY OF LIVED EXPERIENCES
Aug 11, 2026, 17:16 PM -
THE ECONOMIC AND HUMANISTIC BURDEN OF COVID-19 IN HIGH-RISK PEDIATRIC PATIENTS AND THEIR CAREGIVERS
Aug 11, 2026, 17:16 PM -
MEASUREMENT PRECISION MATTERS: PROPR DETECTS TREATMENT EFFECTS MISSED BY EQ-5D-5L IN THE CONVINCE RANDOMIZED TRIAL
Aug 11, 2026, 17:16 PM -
NATIONAL TRENDS IN PATIENT EXPOSURE TO ONCOLOGY EARLY ACCESS PATHWAYS IN FRANCE: A POPULATION-BASEDANALYSIS
Aug 11, 2026, 17:16 PM -
BEYOND HEALTH GAINS: SOCIETAL AND FISCAL VALUE OF VORASIDENIB IN THE EARLY TREATMENT OF IDH-MUTANT GRADE 2 GLIOMA IN GERMANY
Aug 11, 2026, 17:16 PM
